Last update Nov. 21, 2022

Digitoxin

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a digitalis glycoside with actions similar to those of digoxin that is used in the treatment of congestive heart failure and some cardiac arrhythmias. Oral or intravenous administration.

At the date of the last update, we found no published data on its excretion in breast milk.

Its high molecular weight and high binding to plasma proteins make its passage into breast milk unlikely, although its very long half-life (Haustein 1981) could favor it.

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.

 

Alternatives

  • Digoxin ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Digitoxin in other languages or writings:

Group

Digitoxin belongs to this group or family:

Tradenames

Main tradenames from several countries containing Digitoxin in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 765 daltons
Protein Binding > 90 %
pKa 7.18 -
Tmax 4 hours
138 (77 - 234) hours

References

  1. Haustein KO. Interindividual differences in the pharmacokinetics of digitoxin and digoxin during long-term treatment. Eur J Clin Pharmacol. 1981 Jan;19(1):45-51. Abstract

Total visits

3,798

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM